StockData
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. (OKUR) stock

OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30
$2.58−0.17 (-6.18%)

Close on Nov 17, 2026Market cap $104.48MP/E –Yield –

OnKure Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

OnKure Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$61.74M. For fiscal 2025 it was -$62.50M. The highest annual figure on record is -$19.52M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$62.50M–
FY2024Dec 31, 2024-$53.93M–
FY2023Dec 31, 2023-$36.52M–
FY2022Dec 31, 2022-$53.76M–
FY2021Dec 31, 2021-$39.77M–
FY2020Dec 31, 2020-$19.52M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$16.81M–
Q1 FY2026Mar 31, 2026-$15.51M–
Q4 FY2025Dec 31, 2025-$14.02M–
Q3 FY2025Sep 30, 2025-$15.39M–
Q2 FY2025Jun 30, 2025-$16.21M–
Q1 FY2025Mar 31, 2025-$16.88M–
Q4 FY2024Dec 31, 2024-$18.58M-186.8%
Q3 FY2024Sep 30, 2024-$11.40M–
Q2 FY2024Jun 30, 2024-$14.23M–
Q1 FY2024Mar 31, 2024-$9.72M–
Q4 FY2023Dec 31, 2023$21.40M–
Q3 FY2023Sep 30, 2023-$20.85M–
Q2 FY2023Jun 30, 2023-$21.00M–
Q1 FY2023Mar 31, 2023-$16.08M–
Q4 FY2022Dec 31, 2022-$14.54M–
Q3 FY2022Sep 30, 2022-$13.82M–
Q2 FY2022Jun 30, 2022-$12.41M–
Q1 FY2022Mar 31, 2022-$13.00M–
Q4 FY2021Dec 31, 2021-$10.61M–
Q3 FY2021Sep 30, 2021-$12.74M–
Q2 FY2021Jun 30, 2021-$9.22M–
Q1 FY2021Mar 31, 2021-$7.20M–
Q4 FY2020Dec 31, 2020-$6.24M–
Q3 FY2020Sep 30, 2020-$5.09M–
Q2 FY2020Jun 30, 2020-$3.69M–
Q1 FY2020Mar 31, 2020-$4.49M–

More OnKure Therapeutics figures

See a number that looks wrong?